Lars Rydén

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

Joep Perk, Guy De Backer, H. Gohlke et al. · European Heart Journal · 2012 · 8.5K citations · Full text

Medicine, Cardiology, Preventive Medicine +16

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

John W. Eikelboom, Stuart J. Connolly, Jackie Bosch et al. · New England Journal of Medicine · 2017 · 2.4K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure

Milton Packer, Philip A. Poole‐Wilson, Paul W. Armstrong et al. · Circulation · 1999 · 1.2K citations

Medicine, Cardiology, Pharmacology +10

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry

Kornelia Kotseva, Guy De Backer, Dirk De Bacquer et al. · European Journal of Preventive Cardiology · 2019 · 937 citations · Full text

Medicine, Cardiology, Interventional Cardiology +16

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Sonia S. Anand, Jackie Bosch, John W. Eikelboom et al. · The Lancet · 2017 · 880 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12